Advertisement
New Zealand markets closed

  • NZX 50

    11,796.21
    -39.83 (-0.34%)
     

  • NZD/USD

    0.5892
    -0.0013 (-0.22%)
     

  • NZD/EUR

    0.5523
    -0.0022 (-0.39%)
     

  • ALL ORDS

    7,817.40
    -81.50 (-1.03%)
     

  • ASX 200

    7,567.30
    -74.80 (-0.98%)
     

  • OIL

    83.24
    +0.51 (+0.62%)
     

  • GOLD

    2,406.70
    +8.70 (+0.36%)
     

  • NASDAQ

    17,037.65
    -356.67 (-2.05%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • Dow Jones

    37,986.40
    +211.02 (+0.56%)
     

  • DAX

    17,737.36
    -100.04 (-0.56%)
     

  • Hang Seng

    16,224.14
    -161.73 (-0.99%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • NZD/JPY

    91.0710
    -0.1830 (-0.20%)
     

Company News for Aug 4, 2022

Zacks Equity Research
·1-min read

  • Shares of Moderna, Inc. MRNA surged 16% after it announced a $3 billion share buyback plan.

  • Regeneron Pharmaceuticals, Inc.’s REGN shares rose 5.9% after it reported second-quarter 2022 earnings of $9.77 per share, beating the Zacks Consensus Estimate of $8.53 per share.

  • Shares of Horizon Therapeutics Public Limited Company HZNP plummeted 18.5% after it reported second-quarter 2022 revenues of $876.4 million, missing the Zacks Consensus Estimate of $938.8 million.

  • Exelon Corporation’s EXC shares fell 3.3% after it reported second-quarter 2022 earnings of $0.44 per share, missing the Zacks Consensus Estimate of $0.46 per share.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN) : Free Stock Analysis Report
 
Exelon Corporation (EXC) : Free Stock Analysis Report
 
Moderna, Inc. (MRNA) : Free Stock Analysis Report
 
Horizon Therapeutics Public Limited Company (HZNP) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research